放射性碘在遗传性甲状腺髓样癌治疗中的应用。

Radioiodine in the treatment of hereditary medullary carcinoma of the thyroid.

作者信息

Nieuwenhuijzen Kruseman A C, Bussemaker J K, Frölich M

出版信息

J Clin Endocrinol Metab. 1984 Sep;59(3):491-4. doi: 10.1210/jcem-59-3-491.

Abstract

The effect of 131I therapy as an adjunct to surgery in the management of patients with hereditary medullary carcinoma of the thyroid (MCT) was studied in 20 patients from 3 kindreds. Plasma calcitonin levels were measured before and after a dose of 131I sufficient to ablate postoperative thyroid remnants. In patients with residual biochemical MCT no significant reduction of the calcitonin levels was found after administration of radioiodine. In patients with normal postoperative calcitonin levels no (biochemical) recurrence developed 3 months to 2 yr subsequent to radioiodine therapy. It is concluded that 131I therapy as an adjunct to surgery is not indicated in the management of patients with residual hereditary MCT, although 131I may be of value in the prevention of tumor recurrence in patients with normal postoperative calcitonin values.

摘要

对来自3个家族的20例患者进行研究，以探讨¹³¹I治疗作为手术辅助手段在遗传性甲状腺髓样癌（MCT）患者管理中的效果。在给予足以消融术后甲状腺残余组织的¹³¹I剂量前后，测量血浆降钙素水平。在生化检查显示有MCT残留的患者中，给予放射性碘后降钙素水平未显著降低。在术后降钙素水平正常的患者中，¹³¹I治疗后3个月至2年未出现（生化）复发。得出结论，对于残留遗传性MCT的患者，¹³¹I治疗作为手术辅助手段并不适用，尽管¹³¹I可能对预防术后降钙素值正常患者的肿瘤复发有价值。